{"id":"https://openalex.org/W4362545751","doi":"https://doi.org/10.1158/2326-6066.c.6548390","title":"Data from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy","display_name":"Data from Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362545751","doi":"https://doi.org/10.1158/2326-6066.c.6548390"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548390","doi":"https://doi.org/10.1158/2326-6066.c.6548390","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548390","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2326-6066.c.6548390","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103093153","display_name":"Xinqi Wu","orcid":"https://orcid.org/0000-0003-4979-4596","observed_orcids":["https://orcid.org/0000-0003-4979-4596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinqi Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071788399","display_name":"Anita Giobbie\u2010Hurder","orcid":"https://orcid.org/0000-0003-2496-7737","observed_orcids":["https://orcid.org/0000-0003-2496-7737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Giobbie-Hurder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100569863","display_name":"Xiaoyun Liao","orcid":"https://orcid.org/0009-0000-8904-0102","observed_orcids":["https://orcid.org/0009-0000-8904-0102"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoyun Liao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083019296","display_name":"Courtney F. Connelly","orcid":"https://orcid.org/0009-0007-0300-0697","observed_orcids":["https://orcid.org/0009-0007-0300-0697"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Courtney Connelly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080406013","display_name":"Erin M. Connolly","orcid":"https://orcid.org/0000-0003-3230-8061","observed_orcids":["https://orcid.org/0000-0003-3230-8061"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erin M. Connolly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100338383","display_name":"Jingjing Li","orcid":"https://orcid.org/0000-0002-4410-2629","observed_orcids":["https://orcid.org/0000-0002-4410-2629"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jingjing Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070590609","display_name":"Michael P. Manos","orcid":"https://orcid.org/0000-0003-0841-207X","observed_orcids":["https://orcid.org/0000-0003-0841-207X","https://orcid.org/0000-0001-9766-0977"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael P. Manos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049839632","display_name":"Donald P. Lawrence","orcid":"https://orcid.org/0000-0001-5288-9110","observed_orcids":["https://orcid.org/0000-0001-5288-9110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald Lawrence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David McDermott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061431553","display_name":"Mariano Severgnini","orcid":"https://orcid.org/0000-0001-6783-8500","observed_orcids":["https://orcid.org/0000-0001-6783-8500"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mariano Severgnini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jun Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005477709","display_name":"Evisa Gjini","orcid":"https://orcid.org/0000-0002-6951-9279","observed_orcids":["https://orcid.org/0000-0002-6951-9279","https://orcid.org/0009-0004-4495-6255"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evisa Gjini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051793744","display_name":"Ana Lako","orcid":"https://orcid.org/0000-0003-2931-6212","observed_orcids":["https://orcid.org/0000-0003-2931-6212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Lako","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076738875","display_name":"Mikel Lipschitz","orcid":"https://orcid.org/0000-0002-5764-1648","observed_orcids":["https://orcid.org/0000-0002-5764-1648"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mikel Lipschitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044277413","display_name":"Christine J. Pak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christine J. Pak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Sara Abdelrahman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sara Abdelrahman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Rodig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.004800000227987766,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiopoietin-2","display_name":"angiopoietin-2","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-therapy","display_name":"immune checkpoint therapy","score":0.7450000047683716},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.8180000185966492},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.8820000290870667},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.878000020980835},{"id":"https://openalex.org/keywords/anti-vegf-therapy-resistance","display_name":"anti-VEGF therapy resistance","score":0.7599999904632568},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8519999980926514},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/tumor-associated-macrophages","display_name":"tumor-associated macrophages","score":0.7749999761581421},{"id":"https://openalex.org/keywords/m2-macrophages","display_name":"M2 macrophages","score":0.7850000262260437},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7260000109672546},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8140000104904175},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.5759999752044678},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.8610000014305115},{"id":"https://openalex.org/keywords/circulating-biomarkers","display_name":"circulating biomarkers","score":0.5},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.40299999713897705}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8770995140075684},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.783652663230896},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.7388396859169006},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7190431356430054},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5439820289611816},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5431124567985535},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5288957953453064},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.517245352268219},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.49961400032043457},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4860556423664093},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4712287187576294},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.43164947628974915},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4299122095108032},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.4171196222305298},{"id":"https://openalex.org/C2775858924","wikidata":"https://www.wikidata.org/wiki/Q18034009","display_name":"CD163","level":4,"score":0.41027742624282837},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3933536410331726},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3930933177471161},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3562876582145691},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.17069342732429504},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.16320183873176575},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.11870086193084717},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.10233473777770996},{"id":"https://openalex.org/C2779244956","wikidata":"https://www.wikidata.org/wiki/Q184204","display_name":"Macrophage","level":3,"score":0.06568732857704163},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2326-6066.c.6548390","doi":"https://doi.org/10.1158/2326-6066.c.6548390","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548390","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/2326-6066.c.6548390.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548390.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548390.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548390","doi":"https://doi.org/10.1158/2326-6066.c.6548390","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.c.6548390","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2565119421","https://openalex.org/W4392654014","https://openalex.org/W2606765235","https://openalex.org/W4379117716","https://openalex.org/W4366817320","https://openalex.org/W1968014316","https://openalex.org/W4362594333","https://openalex.org/W3102923656","https://openalex.org/W2037598044","https://openalex.org/W4402824828"],"abstract_inverted_index":{"Abstract":[0],"Immune":[1],"checkpoint":[2,46,85,218],"therapies":[3],"targeting":[4],"CTLA-4":[5,98],"and":[6,23,56,73,99,136,155,161,187,213,220,229],"PD-1":[7,100],"have":[8],"proven":[9],"effective":[10],"in":[11,54,59,79,97,109,145,172,193,232],"cancer":[12],"treatment.":[13],"However,":[14],"the":[15,65,71,233,245],"identification":[16],"of":[17,76,148,196,247],"biomarkers":[18],"for":[19,42,216],"predicting":[20],"clinical":[21,199],"outcomes":[22],"mechanisms":[24],"to":[25,61,191,223,243],"overcome":[26],"resistance":[27,60,225],"remain":[28],"as":[29,36,210],"critical":[30],"needs.":[31],"Angiogenesis":[32],"is":[33,50,57],"increasingly":[34],"appreciated":[35],"an":[37,51],"immune":[38,52,84,217,248],"modulator":[39],"with":[40,45,64,93,128,153],"potential":[41],"combinatorial":[43,241],"use":[44],"blockade.":[47],"Angiopoietin-2":[48],"(ANGPT2)":[49],"target":[53],"patients":[55,82,111,197],"involved":[58],"anti-VEGF":[62],"treatment":[63,114,120,224],"monoclonal":[66],"antibody":[67,189],"bevacizumab.":[68],"We":[69],"investigated":[70],"predictive":[72,212],"prognostic":[74,214],"value":[75],"circulating":[77],"ANGPT2":[78,90,108,124,143,170,177,192,206,237],"metastatic":[80],"melanoma":[81],"receiving":[83,198],"therapy.":[86,249],"High":[87],"pretreatment":[88],"serum":[89,107,122,205],"was":[91,151],"associated":[92,127,152],"reduced":[94,129],"overall":[95,132],"survival":[96],"blockade\u2013treated":[101],"patients.":[102],"These":[103],"treatments":[104],"also":[105],"increased":[106,154,178],"many":[110],"early":[112],"after":[113],"initiation,":[115],"whereas":[116,176],"ipilimumab":[117,137],"plus":[118,138],"bevacizumab":[119,139,167],"decreased":[121,156],"concentrations.":[123],"increases":[125],"were":[126],"response":[130],"and/or":[131],"survival.":[133],"Ipilimumab":[134],"increased,":[135],"decreased,":[140],"tumor":[141,157,234],"vascular":[142],"expression":[144,171,180],"a":[146,194,211,239],"subset":[147,195],"patients,":[149],"which":[150],"infiltration":[158],"by":[159],"CD68+":[160],"CD163+":[162],"macrophages,":[163],"respectively.":[164],"In":[165],"vitro,":[166],"blocked":[168],"VEGF-induced":[169],"tumor-associated":[173],"endothelial":[174],"cells,":[175],"PD-L1":[179],"on":[181],"M2-polarized":[182],"macrophages.":[183],"Treatments":[184],"elicited":[185],"long-lasting":[186],"functional":[188],"responses":[190],"benefit.":[200],"Our":[201],"findings":[202],"suggest":[203],"that":[204],"may":[207,221],"be":[208],"considered":[209],"biomarker":[215],"therapy":[219],"contribute":[222],"via":[226],"increasing":[227],"proangiogenic":[228],"immunosuppressive":[230],"activities":[231],"microenvironment.":[235],"Targeting":[236],"provides":[238],"rational":[240],"approach":[242],"improve":[244],"efficacy":[246],"Cancer":[250],"Immunol":[251],"Res;":[252],"5(1);":[253],"17\u201328.":[254],"\u00a92016":[255],"AACR.":[256]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}